Schizophrenia FAQs | VRAYLAR® (cariprazine) Skip to Main content Learn how AbbVie could help you save on VRAYLAR. Call Learn how AbbVie could help you save on VRAYLAR. Call Learn how AbbVie could help you save on VRAYLAR. Call 1-800-678-1605 or click to or click to or click to learn more > For adults in the treatment of schizophrenia. For adults in the treatment of schizophrenia. For adults in the treatment of schizophrenia. Select Condition Major Depressive Disorder Bipolar I Disorder Other Condition Important Safety Information Prescribing Information Medication Guide Cost & Savings Healthcare Professional Site Why VRAYLAR What is VRAYLAR? How VRAYLAR works Taking VRAYLAR Side effects of VRAYLAR About Schizophrenia Talking about schizophrenia What are the symptoms? Sharing your symptoms FAQs Resources Save On VRAYLAR Other Condition HEALTHCARE PROFESSIONAL SITE VRAYLAR Frequently Asked Questions What VRAYLAR Is Taking VRAYLAR Possible Side Effects About Schizophrenia Saving on VRAYLAR What VRAYLAR Is What is VRAYLAR? VRAYLAR ® (cariprazine) is a once-a-day pill, taken with or without food, for the treatment of schizophrenia in adults. How does VRAYLAR work? Medical researchers believe that schizophrenia may be caused by an imbalance of certain chemicals in the brain called neurotransmitters. VRAYLAR is thought to affect the activity of neurotransmitters. However, the exact way VRAYLAR works is unknown. Taking VRAYLAR What should I let my healthcare professional know before starting VRAYLAR? Tell your healthcare provider about any medical conditions and if you: have or have had heart problems or a stroke have or have had low or high blood pressure have or have had diabetes or high blood sugar in you or your family have or have had high levels of total cholesterol, LDL-cholesterol, or triglycerides; or low levels of HDL-cholesterol have or have had seizures (convulsions) have or have had kidney or liver problems have or have had low white blood cell count are pregnant or plan to become pregnant. VRAYLAR may harm your unborn baby. Talk to your healthcare provider about the risk to your unborn baby if you take VRAYLAR during pregnancy. If you become pregnant or think you are pregnant during treatment, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or http://www.womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/ are breastfeeding or plan to breastfeed. It is not known if VRAYLAR passes into breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with VRAYLAR Tell your healthcare provider about all medicines that you take, including prescriptions, over-the-counter medicines, vitamins, and supplements. VRAYLAR may affect the way other medicines work, and other medicines may affect how VRAYLAR works. Do not start or stop any medicines while taking VRAYLAR without talking to your healthcare provider. How should I take VRAYLAR? VRAYLAR is an oral capsule that is taken once daily with or without food. It is important that you take your prescribed dose of VRAYLAR as directed, even if you start to feel better. Besides medicine, is there anything else that can help treat my schizophrenia? In addition to treatment, it’s important to remember to surround yourself with a trusted support system. That can include friends, family, or patient support groups who can help you stay consistent with your treatment. When will VRAYLAR start working? Medications like VRAYLAR tend to work gradually, so it may take some time for you to notice your symptoms improve. That’s why it’s important to take VRAYLAR exactly as prescribed. Who should not take VRAYLAR? Do not take VRAYLAR if you are allergic to any of its ingredients. Get emergency medical help if you are having an allergic reaction (eg, rash, itching, hives, swelling of the tongue, lip, face or throat). Possible Side Effects What are the most common side effects of VRAYLAR? The most common side effects include difficulty moving or slow movements, tremors, uncontrolled body movements, restlessness and feeling like you need to move around, sleepiness, nausea, vomiting, and indigestion. What are other possible side effects of VRAYLAR? Please click here for more information on side effects. What do I do if I think I am having side effects? Have you ever wondered, “Could what I’m feeling be a side effect of my medication?” Call your healthcare provider right away and explain in detail what you are experiencing so they can tell you what to do. Always call your healthcare provider if you have questions about your medication or your dosing. Will VRAYLAR affect my weight? Weight gain has been reported with VRAYLAR. In 6-week clinical studies, patients with schizophrenia who took VRAYLAR experienced an average weight gain of 2.2 pounds, compared to those on placebo who gained about 0.7 pounds. You and your doctor should monitor your weight regularly. Will VRAYLAR affect my blood sugar? An increase in blood sugar has been reported with VRAYLAR. If you have diabetes or risk factors for diabetes (eg, being overweight or family history of diabetes), your blood sugar should be tested before you start VRAYLAR and regularly during treatment. Complications of diabetes can be serious and even life-threatening. Tell your healthcare provider if you have symptoms such as feeling very thirsty, or very hungry, or sick to your stomach, urinating more than usual, or feeling weak, tired, confused, or your breath smells fruity. Will VRAYLAR affect my cholesterol? An increase in cholesterol has been reported with VRAYLAR. Your healthcare provider should check your cholesterol and triglyceride levels before and during treatment. Will VRAYLAR make me feel sleepy or drowsy? In 6-week clinical studies, 7% of patients with schizophrenia who took VRAYLAR felt sleepy or drowsy. In comparison, 6% of patients taking placebo felt sleepy or drowsy. Will VRAYLAR make me feel restless or like I need to move around? Feeling restless or like you need to move around has been reported with VRAYLAR. In the 6-week clinical studies, 11% of patients with schizophrenia who took VRAYLAR felt restless or like they needed to move around (akathisia) as compared to 4% of patients taking placebo. About Schizophrenia How long does schizophrenia last? Schizophrenia is a chronic condition. That means it’s lifelong and there is no cure. But for many people, the symptoms may be helped with treatment. Is schizophrenia hereditary? Schizophrenia is seen more often in people with a sibling or parent (a first-degree relative) who have the condition. Research is being done to try to determine the genes that may be linked to schizophrenia. Saving on VRAYLAR How can I get a savings card for VRAYLAR? You may be eligible for a VRAYLAR savings card. Click here to learn more. INDICATION AND USAGE VRAYLAR is approved in adults for the treatment of schizophrenia. IMPORTANT SAFETY INFORMATION What is the most important information I should know about VRAYLAR? Elderly people with dementia-related psychosis (having lost touch with reality due to confusion and memory loss) taking medicines like VRAYLAR are at an increased risk of death. VRAYLAR is not approved for treating patients with dementia-related psychosis. VRAYLAR and antidepressants increase the risk of suicidal thoughts or actions in people 24 years of age and younger especially within the first few months of treatment or when the dose is changed. Depression and other mental illnesses are the most important causes of suicidal thoughts and actions. Patients on antidepressants and their families or caregivers should watch for new or worsening depression symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when VRAYLAR or the antidepressant is started or when the dose is changed. Report any change in these symptoms immediately to the doctor. VRAYLAR may cause serious side effects, including: Stroke (cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death Neuroleptic malignant syndrome (NMS): Call your healthcare provider or go to the nearest hospital emergency room right away if you have high fever, stiff muscles, confusion, increased sweating, or changes in breathing, heart rate, and blood pressure. These can be symptoms of a rare but potentially fatal side effect called NMS. VRAYLAR should be stopped if you have NMS. Uncontrolled body movements (tardive dyskinesia or TD): VRAYLAR may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking VRAYLAR. Tardive dyskinesia may also start after you stop taking VRAYLAR. Late-occurring side effects: VRAYLAR stays in your body for a long time. Some side effects may not happen right away and can start a few weeks after starting VRAYLAR, or if your dose increases. Your healthcare provider should monitor you for side effects for several weeks after starting or increasing dose of VRAYLAR. Problems with your metabolism, such as: High blood sugar and diabetes: Increases in blood sugar can happen in some people who take VRAYLAR. Extremely high blood sugar can lead to coma or death. Your healthcare provider should check your blood sugar before or soon after starting VRAYLAR and regularly during treatment. Tell your healthcare provider if you have symptoms such as feeling very thirsty, very hungry, or sick to your stomach, urinating more than usual, feeling weak, tired, confused, or your breath smells fruity. Increased fat levels (cholesterol and triglycerides) in your blood: Your healthcare provider should check fat levels in your blood before or soon after starting VRAYLAR and during treatment. Weight gain: Weight gain has been reported with VRAYLAR. You and your healthcare provider should check your weight before and regularly during treatment. Low white blood cell count: Low white blood cell counts have been reported with antipsychotic drugs, including VRAYLAR. This may increase your risk of infection. Very low white blood cell counts, which can be fatal, have been reported with other antipsychotics. Your healthcare provider may do blood tests during the first few months of treatment with VRAYLAR. Decreased blood pressure (orthostatic hypotension): You may feel lightheaded or faint when you rise too quickly from a sitting or lying position. Falls: VRAYLAR may make you sleepy or dizzy, may cause a decrease in blood pressure when changing position (orthostatic hypotension), and can slow thinking and motor skills, which may lead to falls that can cause fractures or other injuries. Seizures (convulsions) Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities: Do NOT drive, operate machinery, or do other dangerous activities until you know how VRAYLAR affects you. VRAYLAR may make you drowsy. Increased body temperature: Do not become too hot or dehydrated during VRAYLAR treatment. Do not exercise too much. In hot weather, stay inside in a cool place if possible. Stay out of the sun. Do not wear too much clothing or heavy clothing. Drink plenty of water. Difficulty swallowing that can cause food or liquid to get into your lungs Who should not take VRAYLAR? Do not take VRAYLAR if you are allergic to any of its ingredients. Get emergency medical help if you are having an allergic reaction (eg, rash, itching, hives, swelling of the tongue, lip, face or throat). What should I tell my healthcare provider before taking VRAYLAR? Tell your healthcare provider about any medical conditions and if you: have or had heart problems or a stroke have or had low or high blood pressure have or had diabetes or high blood sugar in you or your family have or had high levels of total cholesterol, LDL-cholesterol, or triglycerides; or low levels of HDL-cholesterol have or had seizures (convulsions) have or had kidney or liver problems have or had low white blood cell count are pregnant or plan to become pregnant. VRAYLAR may harm your unborn baby. Taking VRAYLAR during your third trimester of pregnancy may cause your baby to have abnormal muscle movements or withdrawal symptoms after birth. Talk to your healthcare provider about the risk to your unborn baby if you take VRAYLAR during pregnancy. There is a pregnancy exposure registry for women who are exposed to VRAYLAR during pregnancy. If you become pregnant or think you are pregnant during treatment, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or http://www.womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/ . are breastfeeding or plan to breastfeed. It is not known if VRAYLAR passes into breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with VRAYLAR. Tell your healthcare provider about all medicines that you take, including prescriptions, over-the-counter medicines, vitamins, and supplements. VRAYLAR may affect the way other medicines work, and other medicines may affect how VRAYLAR works. Do not start or stop any medicines while taking VRAYLAR without talking to your healthcare provider. What are the most common side effects of VRAYLAR? The most common side effects include difficulty moving or slow movements, tremors, uncontrolled body movements, restlessness and feeling like you need to move around, sleepiness, nausea, vomiting, indigestion, constipation, feeling tired, trouble sleeping, increased appetite, and dizziness. These are not all the possible side effects of VRAYLAR. VRAYLAR is available in 0.5 mg, 0.75 mg, 1.5 mg, 3 mg, 4.5 mg, and 6 mg capsules. INDICATIONS AND USAGE VRAYLAR is a prescription medicine used: along with antidepressant medicines to treat major depressive disorder (MDD) in adults to treat depressive episodes that happen with bipolar I disorder (bipolar depression) in adults to treat short-term (acute) manic or mixed episodes that happen with bipolar I disorder in adults and children ages 10 years and older Please see the full Prescribing Information , including Boxed Warnings, and Medication Guide . US-VRAA-250457 You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more. HOME WHY VRAYLAR What is VRAYLAR? How VRAYLAR works Taking VRAYLAR Side effects of VRAYLAR ABOUT SCHIZOPHRENIA Talking about schizophrenia What are the symptoms? Sharing your symptoms FAQs RESOURCES SAVE ON VRAYLAR SITEMAP HOME ABOUT ABBVIE PRESCRIBING INFORMATION ACCESSIBILITY STATEMENT CONTACT US TERMS OF USE PRIVACY NOTICE COOKIES SETTINGS YOUR PRIVACY CHOICES VRAYLAR ® AND ITS DESIGN ARE REGISTERED TRADEMARKS OF FOREST LABORATORIES HOLDINGS LTD., AN ABBVIE COMPANY. VRAYPAY SM IS A SERVICE MARK OF FOREST LABORATORIES HOLDINGS LTD., AN ABBVIE COMPANY. © 2022 ABBVIE COMPANY. ALL RIGHTS RESERVED. LICENSED FROM GEDEON RICHTER PLC. IF YOU ARE A PATIENT, AND HAVE ANY QUESTIONS, PLEASE DISCUSS THEM WITH YOUR DOCTOR OR HEALTHCARE PROVIDER. FOR ADDITIONAL INFORMATION ABOUT VRAYLAR ® , CALL ABBVIE MEDICAL INFORMATION TOLL-FREE AT 1.800.678.1605. US-VRA-220161 You are now leaving VRAYLAR.com Links to other websites are provided as a service to you. By clicking “YES,” you acknowledge and agree that AbbVie makes no guarantees that using any such support groups will result in your desired outcome. AbbVie accepts no responsibility for the content of other sites. Would you like to continue? YES NO US-VRA-220161 You are now leaving VRAYLAR.com Links to other websites are provided as a service to you. By clicking “YES,” you acknowledge and agree that AbbVie makes no guarantees that using any such support groups will result in your desired outcome. AbbVie accepts no responsibility for the content of other sites. Would you like to continue? YES NO US-VRA-220161 For Healthcare Professionals The information provided in this website is intended for U.S. healthcare professionals only. I certify that I am a U.S. healthcare professional. If you choose “NO,” you will remain on the patient website. YES NO US-VRA-220161 You are now leaving VRAYLAR.com Links to other websites are provided as a service to you. By clicking “YES,” you acknowledge and agree that AbbVie makes no guarantees that using any such support groups will result in your desired outcome. AbbVie accepts no responsibility for the content of other sites. Would you like to continue? YES NO US-VRA-220161 You are now being redirected to the VRAYLAR Savings Card activation website, where patients can activate and print a Savings Card. YES NO US-VRA-220161 You are now leaving VRAYLAR.com Links to other websites are provided as a service to you. By clicking “YES,” you acknowledge and agree that AbbVie makes no guarantees that using any such support groups will result in your desired outcome. AbbVie accepts no responsibility for the content of other sites. Would you like to continue? YES NO US-VRA-220161 You are now leaving VRAYLAR.com You are leaving the VRAYLAR (cariprazine) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. Conversely, the presence of this link does not imply the linked site's endorsement of VRAYLAR.com or AbbVie. Do you wish to leave this site? YES NO US-VRA-230180 You are now leaving VRAYLAR.com Links to other websites are provided as a service to you. AbbVie accepts no responsibility for the content of other sites. Would you like to continue? YES NO US-VRAA-220054 For Healthcare Professionals The information provided in this website is intended for U.S. healthcare professionals only. I certify that I am a U.S. healthcare professional. If you choose “NO,” you will remain on the patient website. YES NO US-VRA-230180 You are now leaving VRAYLAR.com You are leaving the VRAYLAR (cariprazine) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. Conversely, the presence of this link does not imply the linked site's endorsement of VRAYLAR.com or AbbVie. Do you wish to leave this site? Yes No US-VRA-230180 For residents of Puerto Rico By selecting ‘continue’ you will enter the VRAYLAR Puerto Rico website, which includes key information presented in Spanish. Cost & Savings information on this site is intended for Puerto Rico residents only. If you are a U.S. resident looking for cost information, please select ‘Back’ and visit the Cost & Savings page. Continue Back US-VRAA-240126 US-VRA-240106 INDICATIONS AND USAGE VRAYLAR is approved in adults for the treatment of schizophrenia. IMPORTANT SAFETY INFORMATION What is the most important information I should know about VRAYLAR? Elderly people with dementia-related psychosis (having lost touch with reality due to confusion and memory loss) taking medicines like VRAYLAR are at an increased risk of death. VRAYLAR is not approved for treating patients with dementia-related psychosis. INDICATIONS AND USAGE VRAYLAR is approved in adults for the treatment of schizophrenia. IMPORTANT SAFETY INFORMATION What is the most important information I should know about VRAYLAR? Elderly people with dementia-related psychosis (having lost touch with reality due to confusion and memory loss) taking medicines like VRAYLAR are at an increased risk of death. VRAYLAR is not approved for treating patients with dementia-related psychosis. INDICATIONS AND USAGE VRAYLAR is approved in adults for the treatment of schizophrenia. IMPORTANT SAFETY INFORMATION What is the most important information I should know about VRAYLAR? Elderly people with dementia-related psychosis (having lost touch with reality due to confusion and memory loss) taking medicines like VRAYLAR are at an increased risk of death. VRAYLAR is not approved for treating patients with dementia-related psychosis. INDICATIONS AND USAGE VRAYLAR is approved in adults for the treatment of schizophrenia. IMPORTANT SAFETY INFORMATION What is the most important information I should know about VRAYLAR? Elderly people with dementia-related psychosis (having lost touch with reality due to confusion and memory loss) taking medicines like VRAYLAR are at an increased risk of death. VRAYLAR is not approved for treating patients with dementia-related psychosis. INDICATION AND USAGE VRAYLAR is approved in adults for the treatment of schizophrenia. IMPORTANT SAFETY INFORMATION What is the most important information I should know about VRAYLAR? Elderly people with dementia-related psychosis (having lost touch with reality due to confusion and memory loss) taking medicines like VRAYLAR are at an increased risk of death. VRAYLAR is not approved for treating patients with dementia-related psychosis. VRAYLAR and antidepressants increase the risk of suicidal thoughts or actions in people 24 years of age and younger especially within the first few months of treatment or when the dose is changed. Depression and other mental illnesses are the most important causes of suicidal thoughts and actions. Patients on antidepressants and their families or caregivers should watch for new or worsening depression symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when VRAYLAR or the antidepressant is started or when the dose is changed. Report any change in these symptoms immediately to the doctor. VRAYLAR may cause serious side effects, including: Stroke (cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death Neuroleptic malignant syndrome (NMS): Call your healthcare provider or go to the nearest hospital emergency room right away if you have high fever, stiff muscles, confusion, increased sweating, or changes in breathing, heart rate, and blood pressure. These can be symptoms of a rare but potentially fatal side effect called NMS. VRAYLAR should be stopped if you have NMS. Uncontrolled body movements (tardive dyskinesia or TD): VRAYLAR may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking VRAYLAR. Tardive dyskinesia may also start after you stop taking VRAYLAR. Late-occurring side effects: VRAYLAR stays in your body for a long time. Some side effects may not happen right away and can start a few weeks after starting VRAYLAR, or if your dose increases. Your healthcare provider should monitor you for side effects for several weeks after starting or increasing dose of VRAYLAR. Problems with your metabolism, such as: High blood sugar and diabetes: Increases in blood sugar can happen in some people who take VRAYLAR. Extremely high blood sugar can lead to coma or death. Your healthcare provider should check your blood sugar before or soon after starting VRAYLAR and regularly during treatment. Tell your healthcare provider if you have symptoms such as feeling very thirsty, very hungry, or sick to your stomach, urinating more than usual, feeling weak, tired, confused, or your breath smells fruity. Increased fat levels (cholesterol and triglycerides) in your blood: Your healthcare provider should check fat levels in your blood before or soon after starting VRAYLAR and during treatment. Weight gain: Weight gain has been reported with VRAYLAR. You and your healthcare provider should check your weight before and regularly during treatment. Low white blood cell count: Low white blood cell counts have been reported with antipsychotic drugs, including VRAYLAR. This may increase your risk of infection. Very low white blood cell counts, which can be fatal, have been reported with other antipsychotics. Your healthcare provider may do blood tests during the first few months of treatment with VRAYLAR. Decreased blood pressure (orthostatic hypotension): You may feel lightheaded or faint when you rise too quickly from a sitting or lying position. Falls: VRAYLAR may make you sleepy or dizzy, may cause a decrease in blood pressure when changing position (orthostatic hypotension), and can slow thinking and motor skills, which may lead to falls that can cause fractures or other injuries. Seizures (convulsions) Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities: Do NOT drive, operate machinery, or do other dangerous activities until you know how VRAYLAR affects you. VRAYLAR may make you drowsy. Increased body temperature: Do not become too hot or dehydrated during VRAYLAR treatment. Do not exercise too much. In hot weather, stay inside in a cool place if possible. Stay out of the sun. Do not wear too much clothing or heavy clothing. Drink plenty of water. Difficulty swallowing that can cause food or liquid to get into your lungs Who should not take VRAYLAR? Do not take VRAYLAR if you are allergic to any of its ingredients. Get emergency medical help if you are having an allergic reaction (eg, rash, itching, hives, swelling of the tongue, lip, face or throat). What should I tell my healthcare provider before taking VRAYLAR? Tell your healthcare provider about any medical conditions and if you: have or had heart problems or a stroke have or had low or high blood pressure have or had diabetes or high blood sugar in you or your family have or had high levels of total cholesterol, LDL-cholesterol, or triglycerides; or low levels of HDL-cholesterol have or had seizures (convulsions) have or had kidney or liver problems have or had low white blood cell count are pregnant or plan to become pregnant. VRAYLAR may harm your unborn baby. Taking VRAYLAR during your third trimester of pregnancy may cause your baby to have abnormal muscle movements or withdrawal symptoms after birth. Talk to your healthcare provider about the risk to your unborn baby if you take VRAYLAR during pregnancy. There is a pregnancy exposure registry for women who are exposed to VRAYLAR during pregnancy. If you become pregnant or think you are pregnant during treatment, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or http://www.womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/ . are breastfeeding or plan to breastfeed. It is not known if VRAYLAR passes into breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with VRAYLAR. Tell your healthcare provider about all medicines that you take, including prescriptions, over-the-counter medicines, vitamins, and supplements. VRAYLAR may affect the way other medicines work, and other medicines may affect how VRAYLAR works. Do not start or stop any medicines while taking VRAYLAR without talking to your healthcare provider. What are the most common side effects of VRAYLAR? The most common side effects include difficulty moving or slow movements, tremors, uncontrolled body movements, restlessness and feeling like you need to move around, sleepiness, nausea, vomiting, indigestion, constipation, feeling tired, trouble sleeping, increased appetite, and dizziness. These are not all the possible side effects of VRAYLAR. VRAYLAR is available in 0.5 mg, 0.75 mg, 1.5 mg, 3 mg, 4.5 mg, and 6 mg capsules. INDICATIONS AND USAGE VRAYLAR is a prescription medicine used: along with antidepressant medicines to treat major depressive disorder (MDD) in adults to treat depressive episodes that happen with bipolar I disorder (bipolar depression) in adults to treat short-term (acute) manic or mixed episodes that happen with bipolar I disorder in adults and children ages 10 years and older Please see the full Prescribing Information , including Boxed Warnings, and Medication Guide . US-VRAA-250457